These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 16155796

  • 1. In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer.
    Wang CX, Koay DC, Edwards A, Lu Z, Mor G, Ocal IT, Digiovanna MP.
    Breast Cancer Res Treat; 2005 Aug; 92(3):251-63. PubMed ID: 16155796
    [Abstract] [Full Text] [Related]

  • 2. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.
    Cancer Res; 2001 Dec 15; 61(24):8887-95. PubMed ID: 11751413
    [Abstract] [Full Text] [Related]

  • 3. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, Leyland-Jones B.
    Cancer Res; 2006 Jul 15; 66(14):7245-52. PubMed ID: 16849573
    [Abstract] [Full Text] [Related]

  • 4. In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab.
    Chen JL, Wang JY, Tsai YF, Lin YH, Tseng LM, Chang WC, King KL, Chen WS, Chiu JH, Shyr YM.
    Menopause; 2013 Jun 15; 20(6):646-54. PubMed ID: 23340260
    [Abstract] [Full Text] [Related]

  • 5. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
    Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY.
    Breast Cancer Res Treat; 2008 Sep 15; 111(2):241-50. PubMed ID: 17955362
    [Abstract] [Full Text] [Related]

  • 6. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D.
    Cancer Res; 2002 Oct 15; 62(20):5703-10. PubMed ID: 12384528
    [Abstract] [Full Text] [Related]

  • 7. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen.
    Chen J, Power KA, Mann J, Cheng A, Thompson LU.
    Exp Biol Med (Maywood); 2007 Sep 15; 232(8):1071-80. PubMed ID: 17720953
    [Abstract] [Full Text] [Related]

  • 8. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D.
    Cancer; 2003 Oct 01; 98(7):1377-85. PubMed ID: 14508823
    [Abstract] [Full Text] [Related]

  • 9. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
    Saeki H, Yanoma S, Takemiya S, Sugimasa Y, Akaike M, Yukawa N, Rino Y, Imada T.
    Oncol Rep; 2007 Aug 01; 18(2):433-9. PubMed ID: 17611667
    [Abstract] [Full Text] [Related]

  • 10. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo.
    Zhang W, Wang L, Fan Q, Wu X, Wang F, Wang R, Ma Z, Yang J, Lu SH.
    Oncol Rep; 2011 Sep 01; 26(3):621-8. PubMed ID: 21687957
    [Abstract] [Full Text] [Related]

  • 11. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT, Metz MZ, Kane SE.
    Breast Cancer Res Treat; 2005 May 01; 91(2):187-201. PubMed ID: 15868447
    [Abstract] [Full Text] [Related]

  • 12. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K.
    Cancer Res; 2006 Jun 01; 66(11):5836-46. PubMed ID: 16740723
    [Abstract] [Full Text] [Related]

  • 13. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M, Yamashita Y, Kubo N, Yashiro M, Ohira M, Ako E, Tanaka H, Muguruma K, Sawada T, Hirakawa K.
    Oncol Rep; 2012 Jul 01; 28(1):49-54. PubMed ID: 22562413
    [Abstract] [Full Text] [Related]

  • 14. Additive effects of trastuzumab and genistein on human breast cancer cells.
    Lattrich C, Lubig J, Springwald A, Goerse R, Ortmann O, Treeck O.
    Anticancer Drugs; 2011 Mar 01; 22(3):253-61. PubMed ID: 21160418
    [Abstract] [Full Text] [Related]

  • 15. [Arsenic trioxide restores ERα expression in ERα-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice].
    Zhang WJ, Xu DF, Fan QX, Wu XA, Wang F, Wang R, Wang LX.
    Zhonghua Zhong Liu Za Zhi; 2012 Sep 01; 34(9):645-51. PubMed ID: 23159075
    [Abstract] [Full Text] [Related]

  • 16. Dietary flaxseed lignan or oil combined with tamoxifen treatment affects MCF-7 tumor growth through estrogen receptor- and growth factor-signaling pathways.
    Saggar JK, Chen J, Corey P, Thompson LU.
    Mol Nutr Food Res; 2010 Mar 01; 54(3):415-25. PubMed ID: 19904759
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G.
    Exp Cell Res; 2005 Apr 01; 304(2):604-19. PubMed ID: 15748904
    [Abstract] [Full Text] [Related]

  • 18. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
    Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J.
    Cancer Res; 1998 Jul 01; 58(13):2825-31. PubMed ID: 9661897
    [Abstract] [Full Text] [Related]

  • 19. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.
    Mol Pharmacol; 2006 Nov 01; 70(5):1534-41. PubMed ID: 16887935
    [Abstract] [Full Text] [Related]

  • 20. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
    Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL.
    Cancer Res; 2002 Jul 15; 62(14):4132-41. PubMed ID: 12124352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.